Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2015

View Archived Issues

Karolinska Institute collaborates with Johnson & Johnson Innovation

Acetyl-CoA carboxylase inhibition modulates inflammation and fibrosis in the liver

Mitsubishi Tanabe participates in GHIT Fund's screening program

GIRK1 shows promise as a prognostic biomarker for ER-positive breast cancer

ID8-Fluc cells used to create clinically relevant ovarian cancer model

Novel mutation linked to FPL

Early results show gene therapy is safe in Leber's hereditary optic neuropathy trial

Novel gene therapy for Niemann-Pick disease type C

Soraphen A, a promising candidate for the treatment of HCV/HIV coinfection

FDA first to approve tiotropium bromide/olodaterol for COPD

Migalastat granted accelerated assessment by EMA for Fabry disease

FDA approves IND for COTI-2 in gynecological cancers

AbbVie completes acquisition of Pharmacyclics

Roche identifies XIAP inhibitors for cancer

Merck & Co. introduces LRRK2 inhibitors

Aurin Biotech patents complement inhibitors

Lysophospholipid S1P1 receptor ligands described in Allergan patent

Alnylam starts phase I trial of ALN-AS1 in patients with acute intermittent porphyria

Bristol-Myers Squibb patent reports GSK-3 inhibitors

Intellipharmaceutics' Rexista receives fast track designation

Cymbalta approved in Japan for fibromyalgia pain

ZS Pharma seeks U.S. approval of ZS-9 for hyperkalemia

Synageva BioPharma files NDA for sebelipase alfa in Japan

European Commission approves Aloxi for pediatric use

FDA permits sale of Roche's Clostridium difficile diagnostic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...